Genentech at ACT 2026

Nov 15–18, 2026 San Antonio, TX ~1.4k attendees Website

Genentech takes part in 6 sessions at ACT 2026 in San Antonio. Its program centres on in vivo gene therapies and on screening drugs for off-target effects across new and established modalities. It also covers in vitro tests for human neurotoxicity and a case study on Nav1.7-associated dysautonomia.

Organization

ACT 2026 Attendance

Genentech

South San Francisco, CA

gene.com

Pharmaceutical companies

Biotechnology company in the Roche Group that discovers, develops and markets medicines, chiefly in oncology, immunology and neuroscience.

Session

Mon Nov 16
2:00pm–5:00pm

In Vivo Gene Therapies: Breakthrough Innovations, Regulatory Roadmaps, and Development Challenges (S04)

Biologics and new modalities · Regulatory · with Pfizer

2:00pmIntroduction (S04-1)Pfizer
2:10pmAdvanced Therapy Medicinal Products: The Journey from Innovation to Clinical Application (S04-2)Genentech
2:40pmMechanism-Driven Strategies for Translational Safety Success in Gene Therapy (S04-3)Attentive Science
3:45pmADME and Toxicology Considerations for the Advancement of Non-viral Gene Therapy Products (S04-4)Editas Medicine
4:15pmGene Therapy Nonclinical Development: Integrating Regulatory Expectations and Scientific Innovation (S04-5)Hartsough Nonclinical Consulting

Talk

Mon Nov 16
2:10pm–2:40pm

Part of In Vivo Gene Therapies: Breakthrough Innovations, Regulatory Roadmaps, and Development Challenges (S04)

Advanced Therapy Medicinal Products: The Journey from Innovation to Clinical Application (S04-2)

Biologics and new modalities

Poster

Mon Nov 16
5:00pm–6:30pm

A Comparative Analysis of In Vitro New Approach Methodologies for Human Neurotoxicity Screening (P503)

Nelson Exhibit Ballroom · Poster P503

Neurotoxicology · New approach methods

Session

Tue Nov 17
2:00pm–5:00pm

The Evolving Landscape of Secondary Pharmacology and Off-Target Assessments in Pharmaceutical Development (S10)

Safety pharmacology · with U.S. Food and Drug Administration

2:00pmTargeted Secondary Pharmacology Panels: Advantages and Applications (S10-1)U.S. Food and Drug Administration
2:15pmDeveloping And Validating Off-Target Screening Methods for New and Established Modalities (S10-2)Genentech
2:45pmAdvancing Secondary Pharmacology: Cross-Industry Insights and a Path Toward Global Harmonization (S10-3)UCB
3:45pmEvolving Selectivity Assessment of Biologic Products with Cell-Based Protein Arrays and Derisking Strategies (S10-4)Johnson & Johnson
4:15pmA Regulatory Perspective on Secondary Pharmacology and Off-Target Assessments for Pharmaceutical Products (S10-5)U.S. Food and Drug Administration

Talk

Tue Nov 17
2:15pm–2:45pm

Part of The Evolving Landscape of Secondary Pharmacology and Off-Target Assessments in Pharmaceutical Development (S10)

Developing And Validating Off-Target Screening Methods for New and Established Modalities (S10-2)

Safety pharmacology

Talk

Wed Nov 18
10:45am–11:10am

Part of Modernizing Drug Development: Advanced Translational Methodologies for CNS and PNS Risk Assessment (S13)

The Complexity of Drug Development Illustrated with Nav1.7-Associated Dysautonomia (S13-4)

Neurotoxicology

Instantly find 20 buyers from Genentech

Get a list of who you should contact, their contact info, and what to say.

Totally free and instant, no sign up necessary!

Not affiliated with or endorsed by the American College of Toxicology (ACT). Organization details are derived from ACT’s published program, exhibitor floor plan and supporter list, and each organization’s own website. Submit a correction